Joaquin F. Mateo - Publications

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology

Published: January 23, 2026

Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.

Journal: Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia

Published: November 18, 2025

ESMO basic requirements for AI-based biomarkers in oncology (EBAI).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 16, 2025

Role of the cross-regulation between Wnt pathway activation and androgen receptor signaling in prostate cancer treatment resistance.

Journal: Cell death and differentiation

Published: September 11, 2025

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Journal: ESMO open

Published: September 01, 2025

Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications.

Journal: Gene

Published: August 29, 2025

The von Willebrand factor/ADAMTS13 ratio as an indicator of venous thromboembolism risk: results from the RETROVE project.

Journal: Journal of thrombosis and thrombolysis

Published: July 30, 2025

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.

Journal: NPJ precision oncology

Published: June 05, 2025

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis.

Journal: European urology oncology

Published: March 31, 2025

Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 21, 2025

Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2025